Year in review: The MANDARA trial showed benralizumab was non-inferior to mepolizumab for #EGPA @RheumNow #ACR24 @rheumarhyme @doktora_ging https://t.co/k5azGQOECB

Looking forward to this Plenary - upadacitinib vs plbo in GCA Similar to GiACTA, 26wk taper w/UPA better than 52wk taper w/PLBO. Too small for safety, but no new rsks Strong argument for DMARDs upfront in GCA... but doesn't help with which 😉 #ACR24 @RheumNow Abstr#0770 https://t.co/MZY4QUazhI

MANDARA Mepolizumab v benralizumab for EGPA BEN is non-inferior Secondary outcomes- less eosinophils and more pts completely off GCs Now approved for EGPA Year in Review #ACR24 Pillinger @RheumNow https://t.co/ThLziABvzu

With increased use of smartphones and wearables there is the opportunity to promote increased physical activity. Christine Pellegrini @RheumNow #ACR24 https://t.co/wSX3EbhVJG

Rheumatic diseases are highly affected by environmental impacts Appreciate the ACR for creating a Climate Change Task Force to proactively and reactively respond to the issues this creates for rheumatologist @ACRheum @dddesir #ACR24 @RheumNow https://t.co/h4jCMa9Fyg

CV risk after gout attack 1.75x increase risk of acute CV risk in first 30 days after gout flare (significant) possibly up to 120 days (didn’t reach significance) @RheumNow #ACR24 year in review Pillinger https://t.co/a2zS8mIw3L

Year in review: Can #gout flares increase CV risk? Cipoletta et al - pts with gout may be at inc risk of CV events for at least 30-120 days after flares. Emphasize CV risk mgt in all patients w/ gout. @RheumNow #ACR24 https://t.co/p1aXVgqkuR

Knee OA Krill oil - No benefit in randomized PBO control study MTX (25 mg) for pain - modest diff in pain (numerical, not WOMAC), lost by 12 mo STEP-9: GLP1 agonist for BMI>30 w knee OA. 60% better than PBO. Wt or other benefits? @RheumNow Michael Pillinger #ACR24 year in review https://t.co/dMw4T0tWLX

Year in review: Semaglutide reduced knee pain over 68 weeks in patients with high BMI and moderate knee #osteoarthritis pain But mechanism of knee pain improvement not yet known if due to wgt loss or other mechanisms. @Rheumnow #ACR24 @rheumarhyme @theactiverheum https://t.co/PkrcIMbgPl

Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7

Diagnostic work up for sarcoidosis. Think of CVID as an important differential @RheumNow #ACR2024 #sarcoidosis https://t.co/DvJzkN3ZjY